A phase 1 study of LY4101174 (ETx-22), an antibody-drug conjugate targeting nectin-4, in patients with advanced or metastatic urothelial cancer and other solid tumors (trial in progress)

被引：0
|
作者：
Rosenberg, Jonathan
Sabatier, Renaud
Viceneux, Armelle
Rouge, Thibault De la Motte
Champiat, Stephane
Lebellec, Loic
Barthelemy, Philippe
Sonpavde, Guru
Gao, Xin
Niglio, Scot
Zhang, Tian
Gedye, Craig
Galsky, Matthew
Milowsky, Matthew
Reimers, Melissa
Weickhardt, Andrew
Grande, Enrique
Castellano, Daniel E.
Bilen, Mehmet
Patnaik, Amita
Zerbib, Robert
Balbas, Minna
Xu, Xiaojian
Aptaker, Kaitlyn
Balar, Arjun V.
Awada, Ahmad H.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT084
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT084
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody-drug conjugate, in patients with breast cancer and other advanced solid tumors
    Rosen, Lee S.
    Wesolowski, Robert
    Baffa, Raffaele
    Liao, Kai-Hsin
    Hua, Steven Y.
    Gibson, Brenda L.
    Pirie-Shepherd, Steven
    Tolcher, Anthony W.
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (01) : 120 - 130
  • [32] First-in-human study of the B7-H4 antibody-drug conjugate (ADC) AZD8205 in patients with advanced/metastatic solid tumors
    Meric-Bernstam, Funda
    Oh, Do-Youn
    Naito, Yoichi
    Shimizu, Toshio
    Chung, Vincent
    Park, Haeseong
    Gaillard, Stephanie
    Wang, Fujun
    Cooper, Zachary A.
    Kinneer, Krista
    Rebelatto, Marlon
    Kirby, Lyndon
    Luheshi, Nadia
    Miller, Neil
    Varga, Andreea
    Mileshkin, Linda R.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [33] Phase 1 Dose-Escalation Study of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor α-Targeting Antibody-Drug Conjugate, in Patients With Solid Tumors
    Moore, Kathleen N.
    Borghaei, Hossein
    O'Malley, David M.
    Jeong, Woondong
    Seward, Shelly M.
    Bauer, Todd M.
    Perez, Raymond P.
    Matulonis, Ursula A.
    Running, Kelli L.
    Zhang, Xiaoyan
    Ponte, Jose F.
    Ruiz-Soto, Rodrigo
    Birrer, Michael J.
    CANCER, 2017, 123 (16) : 3080 - 3087
  • [34] Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies
    Jonasch, Eric
    Call, Justin
    Kambhampati, Swetha
    Caimi, Paolo
    Curti, Brendan
    Diefenbach, Catherine
    Heath, Elisabeth
    Park, Steven
    Kornblum, Noah
    Li, Weidong
    Reimers, Melissa
    Spurgeon, Stephen
    Vaishampayan, Ulka
    Ye, Dingwei
    Zhang, Li
    Zhao, Weili
    Chen, Zhu
    Hunder, Naomi
    Ma, Sharon
    Song, Eric
    Garmezy, Benjamin
    ONCOLOGIST, 2023, 28
  • [35] Phase 1 study of the antibody-drug conjugate (ADC) SGN-LIV1A in patients with heavily pretreated metastatic breast cancer
    Forero-Torres, A.
    Modi, S.
    Specht, J.
    Miller, K.
    Weise, A.
    Burris, H., III
    Liu, M.
    Krop, I.
    Pusztai, L.
    Kostic, A.
    Li, M.
    Mita, M.
    CANCER RESEARCH, 2017, 77
  • [36] A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors
    Gentry T. King
    Keith D. Eaton
    Brandon R. Beagle
    Christopher J. Zopf
    Gilbert Y. Wong
    Heike I. Krupka
    Steven Y. Hua
    Wells A. Messersmith
    Anthony B. El-Khoueiry
    Investigational New Drugs, 2018, 36 : 836 - 847
  • [37] A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors
    King, Gentry T.
    Eaton, Keith D.
    Beagle, Brandon R.
    Zopf, Christopher J.
    Wong, Gilbert Y.
    Krupka, Heike I.
    Hua, Steven Y.
    Messersmith, Wells A.
    El-Khoueiry, Anthony B.
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (05) : 836 - 847
  • [38] Phase 1 study of SGN-ALPV, a novel, investigational vedotin antibody-drug conjugate directed to ALPP/ALPPL2 in advanced solid tumors (SGNALPV-001, trial in progress)
    Lakhani, Nehal J.
    Friedman, Claire Frances
    Perez, Cesar Augusto
    Wehr, Alison
    McGoldrick, Suzanne M.
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [39] Phase 1 study of SGN-PDL1V, a novel, investigational vedotin antibody-drug conjugate directed to PD-L1, in patients with advanced solid tumors (SGNPDL1V001, trial in progress)
    Patnaik, Amita
    Call, Justin A.
    Spreafico, Anna
    Nabell, Lisle
    Yan, Mingjin
    Forero-Torres, Andres
    Gillison, Maura L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [40] Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
    Sheng, Xinan
    Yan, Xieqiao
    Wang, Lin
    Shi, Yanxia
    Yao, Xin
    Luo, Hong
    Shi, Benkang
    Liu, Jiyan
    He, Zhisong
    Yu, Guohua
    Ying, Jianming
    Han, Weiqing
    Hu, Changlu
    Ling, Yun
    Chi, Zhihong
    Cui, Chuanliang
    Si, Lu
    Fang, Jianmin
    Zhou, Aiping
    Guo, Jun
    CLINICAL CANCER RESEARCH, 2021, 27 (01) : 43 - 51
12345